WP1066 Disrupts Janus Kinase-2 and Induces Caspase-Dependent Apoptosis in Acute Myelogenous Leukemia Cells

Abstract

Several cytokines and growth factors that stimulate the proliferation of acute myelogenous leukemia (AML) cells transduce their signals by activating the transcription factor Janus-activated kinase 2 (JAK2). Accordingly, the inhibition of JAK2 or of its downstream signaling pathways suppresses the proliferation of AML cells. Because (E)-3(6-bromopyridin-2-yl)-2-cyano-N-((S0-1-phenylethyl)acrylamide) (WP1066) is a novel analogue of the JAK2 inhibitor AG490, we tested its activity in AML cells and investigated its mechanism of action. Using clonogenic assays, we found that although WP1066 had a marginal effect on normal marrow progenitors, it inhibited the proliferation of AML colony-forming cells obtained from patients with newly diagnosed AML and that of the AML cell lines OCIM2 and K562. WP1066 inhibited OCIM2 cell multiplication by inducing accumulation of cells at the G 0 -G 1 phase of the cell cycle. Similar to its parent compound AG490, WP1066 inhibited the phosphorylation of JAK2, but unlike AG490, WP1066 also degraded JAK2 protein, thereby blocking its downstream signal transducer and activator of transcription (STAT) and phosphoinositide-3-kinase pathways. These effects resulted in the activation of the caspase pathway. Incubation of both OCIM2 and K562 cells with WP1066 activated caspase-3, induced cleavage of poly(ADP-ribose) polymerase, and caused caspase-dependent apoptotic cell death. Thus, WP1066 is a potent JAK2 inhibitor whose effects in AML and other hematologic malignancies merit further investigation. [Cancer Res 2007;67(23):11291-9]

Dehydrocostuslactone disrupts signal transducers and activators of transcription 3 through up-regulation of suppressor of cytokine signaling in breast cancer cells

“…Activated STAT3 in turn signals to a variety of key downstream molecules, including Bcl-XL, Bcl-2, Mcl-1, and survivin, the consequence of which is cell death inhibition and promotion of cell survival (6,7,38). Hyperactivation of JAK/ STAT3 results in altering the response of tumor cells to chemotherapy (39,40), and recent studies have indicated that inhibition of the JAK/STAT3 pathway has consistently been associated with triggering of apoptosis in cancer (41,42). Our results show that DHE treatment decreases the activation of JAK1/2, followed by a decrease of STAT3 phsophorylation (Fig.…”

Persistent Cytomegalovirus Infection in Amniotic Membranes of the Human Placenta

“…These drugs included S31-201, an inhibitor of phosphorylation and dimerization, 66 WP1066, an inhibitor of JAK2 tyrosine kinase, 67 and STA21, an inhibitor of STAT3 dimerization and DNA binding. 68 Treatment with STAT3 inhibitors blocked survivin induction in infected AmEpCs, but not in vehicle dimethyl sulfoxideetreated cells ( Figure 5E).…”

STAT5 in human basophils: IL‐3 is required for its FcεRI‐mediated phosphorylation

“…As no specific STAT5 inhibitor was available, the Janus kinase 2 (JAK2) inhibitor WP1066 (Sigma-Aldrich) (20) was used, since the IL-3 induced phosphorylation of STAT5 is performed by JAK2 (21). Next to WP1066 also the effect of Syk-inhibitor Piceatannol (Sigma-Aldrich) (22) was analyzed, as it has been shown that STAT5 is not only phosphorylated by JAK2, but could be phosphorylated by Syk as well (23,24).…”